New Delhi [India], May 9: Shares of Park Medi continued their upward momentum, emerging as one of the standout performers in the healthcare space after delivering robust gains since their market debut in December. The stock has remained on a steady rally, touching multiple record highs amid growing investor confidence in the company’s long-term expansion strategy and improving operational performance.

The healthcare company has surged nearly 70% so far in CY2026, climbing to ₹250 per share and significantly outperforming broader benchmark indices. The sharp rally has also pushed the company’s market capitalisation beyond the ₹10,000 crore mark, reaching ₹10,787 crore as of Friday’s closing session.

Market analysts believe the momentum may continue, supported by the company’s scalable and affordable healthcare model, expanding hospital footprint, and strong positioning in North India’s rapidly growing healthcare market.

Operational indicators have also remained encouraging. During the first nine months of FY26, occupancy levels improved to 65%, while Average Revenue Per Occupied Bed (ARPOB) stood at ₹27,406, indicating a gradual shift toward higher-value treatments and a better patient mix. Brokerage firm Khandwala Securities noted that stable patient volumes and improving treatment quality continue to support revenue growth and profitability.

India’s healthcare sector has also witnessed significant structural expansion, growing from US$110 billion in 2016 to US$372 billion in 2023, with estimates projecting the market to reach US$638 billion by 2025. Analysts expect companies with scalable hospital networks and affordable care models to benefit the most from this long-term demand cycle.

The brokerage further highlighted that low bed density across North India, rising healthcare awareness, and increasing formalisation of the sector provide strong tailwinds for the company. Park Medi plans to expand its capacity to more than 5,000 beds by FY28, while maintaining a near debt-free balance sheet and stable margins.

Given its aggressive expansion pipeline, healthy financial position, and improving operational metrics, Khandwala Securities has maintained an ‘Overweight’ rating on the stock, citing strong long-term revenue visibility and sustained growth potential.